Prothena Corporation plc To Host Webcast And Conference Call To Discuss Interim Phase 1 Data Of Ongoing NEOD001 Study In Patients With AL Amyloidosis On May 2
Published: May 02, 2014
DUBLIN, May 1, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfolding or cell adhesion, announced today that it will host a live webcast and conference call on Friday, May 2, 2014 at 4:30 p.m. ET (or 1:30 p.m. PT) to review interim clinical data from the ongoing Phase 1 study of NEOD001 presented as part of the poster session at the XIV International Symposium on Amyloidosis earlier this week.
Help employers find you! Check out all the jobs and post your resume.